AstraZeneca amends license deal with Chinese biotech; Chinese protein-based vaccine gets manufacturing OK
In an effort to boost the supply of its AAV Covid-19 vaccine abroad, AstraZeneca has amended its license agreement with Biokangtai to commercialize the drug in mainland China, Pakistan and Indonesia, Biokangtai announced Wednesday.
Biokangtai will market, manufacture and distribute the drug to ease the shortened supply and make the vaccine more accessible. The vaccine has been approved in 185 countries so far, the company said in a press release, but shortened supply, coupled with issues surrounding rare, but fatal, blood clots, have led vaccination numbers to stall out.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters